<DOC>
	<DOCNO>NCT00242606</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety tolerance drug Lamotrigine Levetiracetam initial monotherapy patient newly diagnose epilepsy .</brief_summary>
	<brief_title>Lamotrigine Versus Levetiracetam Initial Monotherapy Epilepsy</brief_title>
	<detailed_description>Epilepsy second frequent neurologic disease ( prevalence 0.5 % - 1 % [ Brodie et al . 1997 ] ) . About 30 % epilepsy patient ( include many child ) suffer intractable seizure [ Kwan &amp; Brodie 2000 ] . Therefore new drug expansion permission drug limit approval , respectively , need . Levetiracetam new potent antiepileptic drug nearly ideal pharmacokinetic property side effect [ Patsalos 2000 ] , approve Germany add-on therapy patient &gt; 15 year age focal epilepsy . Due cognitive side effect efficacy , Lamotrigine become standard therapy focal generalize epilepsy patient &gt; 11 year age . Its disadvantage possibility severe allergic reaction limit speed dose increment . Comparisons : Patients newly diagnose epilepsy treat either Lamotrigine Levetiracetam . Rate seizure-free patient first 6 week trial ( main outcome criterion ) well rate seizure-free patient last 16 week total 26 week observation period , time first seizure appear , time patient take study medication , safety quality life treatment compare .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Age ≥ 12 year Body weight ≥ 30kg ( patient 1215 year age ) ≥ 40kg ( patient 16 year age ) , respectively Either one epileptic seizure high risk relapse ( partial seizure semiology , MRI lesion pathological focal EEG finding ) newly diagnose epilepsy ( ≥ 2 unprovoked seizure ) least 1 seizure within past 3 month begin trial participance Treatment maximum one anticonvulsant drug time inclusion Fertile woman ≥ 16 year age must use least one follow contraceptive least one month prior initiation trial participance : Oral contraceptive , contraceptive diaphragm , intrauterine contraceptive device ( coil ) , tube ligation . For girl 12 15 year age write confirmation sexual abstinence , give person care custody child , sufficient . Informed consent proband write form inform character , relevance consequence clinical trial , additional informed consent give person care custody child patient 12 17 year age , respectively . Patients nonepileptic seizure acute symptomatic seizure whose cause correct Patients suffer absence seizure simple partial seizure without motor sign ( aura ) Patients chronic focal epilepsy epileptic state medical history Patients progressive neurological , degenerative malignant disease clinically relevant investigator 's point view ( e.g . cardiovascular endocrinic disease ) Patients treat Levetiracetam Lamotrigine Patients know manifest renal insufficiency ( creatinine clearance &lt; 80 mL/min ) Patients known hypersensitivity Levetiracetam , Lamotrigine another component trial drug Patients attend legal guardian Patients suffer psychiatric disease affective disorder ( within past 6 month ) , treat electric convulsive therapy , tranquilize agent , monoamine oxidase inhibitor CNSactive sympathomimetics ( e.g . methylphenidate ) Patients suffer alcohol drugaddiction within past 12 month Pregnant breastfeed woman Patients participate another clinical trial within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Newly diagnose epilepsy</keyword>
	<keyword>Initial monotherapy</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Lamotrigine</keyword>
</DOC>